Clinical data | |
---|---|
Trade names | Restas |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral, Intravenous |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 80-90% |
Metabolism | Hepatic |
Elimination half-life | 60-90 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C19H16ClFN2O |
Molar mass | 342.80 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Flutoprazepam (Restas) is a drug which is a benzodiazepine. It was patented in Japan by Sumitomo in 1972[1] and its medical use remains mostly confined to that country. Its muscle relaxant properties are approximately equivalent to those of diazepam - however, it has more powerful sedative, hypnotic, anxiolytic and anticonvulsant effects and is around four times more potent by weight compared to diazepam.[2] It is longer acting than diazepam due to its long-acting active metabolites,[3] which contribute significantly to its effects.[4] Its principal active metabolite is n-desalkylflurazepam, also known as norflurazepam, which is also a principal metabolite of flurazepam (trade name Dalmadorm/Dalmane).[5][6]
Flutoprazepam is typically used for the treatment of severe insomnia and may also be used for treating stomach ulcers.[7]
Flutoprazepam does not fall under the international Convention on Psychotropic Substances of 1971, and is currently unscheduled in the United States.[8]